UC Davis Health Ventures Makes First Investment in Delix Therapeutics

September 10, 2025 - 17:24

UC Davis Health Ventures, a branch of the Innovation and Economic Development Office at the University of California, Davis, has announced its inaugural investment from the Investing in the Future of Medicine (IFM) Fund. This significant financial backing is directed towards Delix Therapeutics, a promising spinout from UC Davis.

Delix Therapeutics is at the forefront of developing innovative non-hallucinogenic neuroplastogens aimed at treating major depressive disorder (MDD) and other serious neuropsychiatric and neurodegenerative conditions. This investment marks a pivotal moment for both the IFM Fund and Delix, as it underscores a commitment to advancing groundbreaking therapies that could transform the landscape of mental health treatment.

By supporting Delix, UC Davis Health Ventures is not only fostering local innovation but also contributing to the broader mission of enhancing patient care through scientific advancements. The collaboration highlights the potential for academic research to translate into viable medical solutions that address critical health challenges.